Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

PFE

Pfizer (PFE)

Pfizer Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NYSE:PFE
FechaHoraFuenteTítuloSímboloCompañía
14/02/202516:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:PFEPfizer Inc
14/02/202513:08Edgar (US Regulatory)Form 13F-HR - Quarterly report filed by institutional managers, HoldingsNYSE:PFEPfizer Inc
13/02/202509:00Business WirePfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate CancerNYSE:PFEPfizer Inc
13/02/202508:13PR Newswire (Canada)ViiV Soins de santé et l'Alliance pharmaceutique pancanadienne (APP) concluent les négociations avec succès concernant APRETUDE pour la prophylaxie préexposition au VIH-1NYSE:PFEPfizer Inc
13/02/202508:10PR Newswire (Canada)ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure ProphylaxisNYSE:PFEPfizer Inc
12/02/202513:51Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NYSE:PFEPfizer Inc
12/02/202511:15Business WireU.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaNYSE:PFEPfizer Inc
10/02/202516:00Business WirePfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)NYSE:PFEPfizer Inc
04/02/202507:11Edgar (US Regulatory)Form 8-K - Current reportNYSE:PFEPfizer Inc
04/02/202505:45Business WirePfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 GuidanceNYSE:PFEPfizer Inc
03/02/202505:45Business WirePfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER TrialNYSE:PFEPfizer Inc
28/01/202505:45Business WirePfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers SymposiumNYSE:PFEPfizer Inc
25/01/202514:00Business WirePfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal CancerNYSE:PFEPfizer Inc
21/01/202517:26Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NYSE:PFEPfizer Inc
10/01/202505:45Business WirePfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder CancerNYSE:PFEPfizer Inc
06/01/202509:00Business WirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ConferenceNYSE:PFEPfizer Inc
20/12/202413:03Business WireU.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerNYSE:PFEPfizer Inc
19/12/202409:00Business WirePfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with AnalystsNYSE:PFEPfizer Inc
18/12/202408:03IH Market NewsDow May Regain Ground After Longest Losing Streak Since 1978NYSE:PFEPfizer Inc
17/12/202415:38IH Market NewsDow Extends Losing Streak To Nine Days, Nasdaq Pulls Back Off Record HighNYSE:PFEPfizer Inc
17/12/202405:45Business WirePfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 GuidanceNYSE:PFEPfizer Inc
12/12/202416:25Business WirePfizer Declares First-Quarter 2025 DividendNYSE:PFEPfizer Inc
12/12/202407:15Business WirePfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast CancerNYSE:PFEPfizer Inc
10/12/202409:00Business WirePfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial GuidanceNYSE:PFEPfizer Inc
10/12/202408:05GlobeNewswire Inc.Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer SymposiumNYSE:PFEPfizer Inc
05/12/202416:06Business WirePfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCSNYSE:PFEPfizer Inc
20/11/202405:45Business WirePfizer Announces New Chief Scientific Officer and President, Research & DevelopmentNYSE:PFEPfizer Inc
20/11/202403:00Business WireEuropean Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without InhibitorsNYSE:PFEPfizer Inc
29/10/202408:09IH Market NewsFutures Pointing To Modestly Lower Open On Wall StreetNYSE:PFEPfizer Inc
29/10/202405:45Business WirePfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 GuidanceNYSE:PFEPfizer Inc
 Showing the most relevant articles for your search:NYSE:PFE